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Abstract
Purpose—There are no published data from specific regions of sub-Saharan Africa describing 
the clinical and pathological characteristics and molecular subtypes of invasive breast cancer by 
ethnic group. The purpose of this study was to investigate these characteristics among the three 
major ethno-cultural groupings in Kenya.
Methods—The study included women with pathologically-confirmed breast cancer seen between 
March 2012 and May 2015 at 11 hospitals throughout Kenya. Socio-demographic, clinical, and 
reproductive data were collected by questionnaire, and pathology review and 
immunohistochemistry were performed centrally.
Results—The 846 cases included 661 Bantus (78.1%), 143 Nilotes (16.9%), 19 Cushites (2.3%), 
and 23 patients of mixed ethnicity (2.7%). In analyses comparing the two major ethnic groups, 
Bantus were more educated, more overweight, had an older age at first birth and had a younger 
age at menopause than Nilotes (p<0.05 for all comparisons). In analyses restricted to definitive 
surgery specimens, there were no statistically significant differences in tumour characteristics or 
molecular subtypes, although the Nilote tumours tended to be larger (OR for ≥ 5 cm vs. < 2 cm: 
3.86, 95%CI: 0.77, 19.30) and were somewhat more likely to be HER2-enriched (OR for HER2-
enriched vs. Luminal A/B: 1.41, 95%CI: 0.79, 2.49).
Conclusion—This case series showed no significant differences in breast cancer tumour 
characteristics or molecular subtypes, but significant differences in socio-demographic 
characteristics and reproductive factors, among the three major ethnic groups in Kenya. We 
suggest further evaluation of ethnic differences in breast cancer throughout the genetically and 
culturally diverse populations of sub-Saharan Africa.
Keywords
Breast cancer; Kenya; Ethnic differences; Ethnicity; sub Saharan Africa
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BACKGROUND
Breast cancer (BC) is the most common female malignancy worldwide, accounting for 1.7 
million new cases and 521,900 deaths in 2012.[1] According to the Nairobi Population-
based Cancer Registry, breast cancer is the most common malignancy in Kenyan women, 
accounting for 23% of all incident cases.[2]
The effect of race and ethnicity on breast cancer (BC) stage of presentation, tumor biology 
and treatment response has been the subject of much investigation and controversy, with 
numerous studies reporting that the distribution of BC molecular subtypes differs among 
various races and ethnic groups.
A qualitative systematic review of breast cancer demographics, size, stage, grade, 
histological type, extra-mammary involvement, and hormone receptor status in patients from 
Africa, the Middle East, Eastern Europe, Mexico, the Caribbean and South America reported 
that women with BC in these regions present with large aggressive tumors, and that distant 
metastases are frequently present at the time of diagnosis.[3] Compared with White 
American women, Black African women have also been reported to be younger at diagnosis,
[4] to have a higher frequency of triple negative tumors,[5] and to be more likely to present 
with Stage III/IV disease.[6] A review of the histopathological differences between BC in 
African American (AA) and White Americans also reports that the former tend to have a 
higher nuclear grade, a higher proportion of lymph node positive tumors, and a younger age-
specific incidence of triple negative tumors as compared to White Americans.[7]
Furthermore, a recent registry data review from South Africa reported that similar to the 
Western populations, the age distribution for breast cancer is bimodal in both Black and 
White South African women, however Black South African women had a younger age 
distribution of early onset breast cancer than all other groups studied.[8]
In Kenya, there are approximately 40–50 tribes which can be divided into 3 main ethno-
cultural groupings: the Bantus who originated from West Africa after 400 AD, the Nilotic 
tribes who migrated from regions of the present day Sudan and Egypt around 400 AD, and 
the Cushitic tribes who came from northern Africa around 2000 BC (Fig 1a).
The largest ethnic groups in Kenya, the Kikuyus, are of Bantu ancestry, while the Luos 
residing in the western part of Kenya are of Nilotic descent. The populations that inhabit the 
northern parts of Kenya belong to the Cushitic lineage.
The objective of this study was to investigate the differences in-patient, clinical and 
pathological characteristics of breast cancer in the three major ethno-cultural groupings in 
Kenya, given their distinct ancestral origin.
METHODS
Study design and setting
This was a Kenya-wide study involving a total of 11 health institutions (Supplementary 
Table 1) that recruited patients with pathologically confirmed breast cancer between March 
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2012 and May 2015. The study was coordinated by Aga Khan University Hospital, Nairobi, 
which is a 300-bed private not-for-profit hospital that provides tertiary level health care 
services in Kenya. The collaborating hospitals in this study are located in various parts of 
Kenya and their patient catchment area reflects the distribution of the total population and 
the three major ethnic groups (Fig. 1b).
Data collection
Relevant socio-demographic, reproductive, and clinical data were collected from all 
consenting patients using structured questionnaires and clinical data abstraction case report 
forms.
The ethnicity of patients was determined through self-reporting by respondents of their 
parents’ and maternal and paternal grandparents’ tribal affiliations. The tribes were assigned 
to the corresponding three major ethnic groups; Bantu, Nilotes and Cushites[9] If all 
maternal and paternal grandparents and parents did not belong to the same tribe, that 
patient’s ethnicity was categorized as mixed. Due to sparse numbers, patients reporting 
“mixed” ethnicity (N=23, 2.7%) were excluded from the analytic population.
All breast cancer tissues blocks were submitted to Aga Khan University Hospital, Nairobi to 
undergo central pathology review and immunohistochemistry. Tumor size, tumor grade, 
presence of lympho-vascular invasion, lymph node metastases and extra nodal extension 
were documented. ER/PR/HER2 status was analyzed on the Dako Automated platform as 
previously reported,[10] and tumors were assigned into 3 major breast cancer molecular 
subtypes based on immunohistochemistry: ER and/or PR positive and HER2 positive or 
negative (Luminal A/B), ER/PR negative and HER2 positive (HER2 enriched), and ER/PR 
and HER2 negative (Triple Negative).
Data entry and verification
All data were double entered. If data were missing, or needed clarification, an additional 
secondary review of the patient files was carried out by the data collection team. Finally, 
SQL scripts were prepared to facilitate data extraction.
Data Analysis
Distributions of socio-demographic and reproductive risk factors, tumor pathology 
characteristics, and tumor hormone receptor status were examined across the three ethnic 
groups (Bantu, Nilotes, and Cushite) and evaluated by Chi-square and Fisher exact tests as 
appropriate. Because of the small numbers of Cushite patients, these statistical tests were 
also rerun after restricting the analysis to the two largest ethnic groups, Bantus and Nilotes. 
Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence 
intervals (95% CIs) for associations between Bantu or Nilote ethnicity and the tumor 
characteristics (tumor pathology characteristics and hormone receptor status). Risk factors 
associated with both ethnicity and the tumor characteristics of interest were included in 
multivariate logistic regression models, and the final models were determined using 
backwards elimination. In exploratory analyses attempting to better understand observed 
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risk factor associations with ethnic group, we also evaluated interrelationships between 
select socio-demographic characteristics with tumor characteristics.
Analyses of socio-demographic, reproductive factors and hormone receptor status included 
all participants with relevant data. In contrast, the tumor pathology characteristics (tumor 
size, tumor grade, lympho-vascular invasion, lymph node metastasis, and extranodal 
extension) were only analyzed in the 396 (48.1%) cases that underwent definitive surgery. 
All analyses were performed using SAS 9.3 (SAS Institute, Inc., Cary, NC) and statistical 
significance was defined as p<0.05.
RESULTS
A total of 823 female study patients with invasive breast tumors were included in the 
analysis, 661 (80.3%) were Bantus, 143 (17.4%) were Nilotes, and 19 (2.3%) were Cushites. 
Of these 823 study participants, 427 (51.9%) were diagnosed by core biopsy only, and 396 
(48.1%) had both a core biopsy and definitive surgery (lumpectomy or mastectomy). 351 
(53.1%) of the Bantus, 37 (25.9%) of the Nilotes, and 8 (42.1%) of the Cushites had 
definitive surgery.
Sociodemographic and Behavioral Characteristics
Overall, the majority (53.9%) of women were younger than age 50 years at breast cancer 
diagnosis, with a median (interquartile range) age of 48 (40-57) years (Table 1). Whereas 
median age at diagnosis was similar for Bantus (48 years) and Nilotes (52 years), the median 
age at diagnosis for Cushites was much younger (36 years) (p=0.03). About half (50.2%) of 
the women received only primary school or no education. The most common occupations 
were farmer (30.8%) and employed worker (23.3%), and only 18.5% said they worked as 
housewives. By body mass index (BMI, kg/m2), nearly 70% of the women were overweight 
(39.2%) or obese (29.5%). Nearly half (42.7%) of the women were exposed to smoking, but 
very few of them (3.3%) reported ever having smoked or used smokeless tobacco 
themselves, and only 8.5% used alcohol.
When the analytic population was limited to Bantus and Nilotes, Bantu patients were 
slightly more educated (51.6% vs. 46.2% with secondary education or above) and slightly 
more overweight or obese (70.1% vs. 63.2%), and they were more likely to work as farmers 
(34.0% vs. 20.3%). Nilote patients, on the other hand, were more likely to work as employed 
workers (31.5% vs. 21.9%) or housewives (26.6% vs. 15.6%).
Reproductive Health Factors
In terms of reproductive health factors in the overall study population, nearly all of the 
participants reported having normal (age 12-14 years) or late (age ≥15 years) menarche 
(49.9% and 49.0%, respectively) (Table 2). Most women (67.9%) had at least three children, 
for most (62.2%) their age at first pregnancy was between the ages of 20 and 29 years, and 
the vast majority (90.1%) reported at least 15 cumulative months of breastfeeding. A little 
less than half (48.1%) of participants were postmenopausal at diagnosis, among whom most 
(57.9%) reported an age at menopause <50 years. The majority (92.2%) of patients reported 
no family history of breast cancer.
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Though based on small numbers, the Cushites seemed to present with a different 
reproductive profile as compared with the Bantus and Nilotes: a greater proportion of 
Cushites were <20 years at first pregnancy (52.6% vs. 24% (Bantus) and 35% (Nilotes); 
p=0.0008) and were premenopausal at diagnosis (73.7% vs. 52.7% (Bantus) and 45.1% 
(Nilotes); p=0.04). When reproductive health factors in Bantus and Nilotes were compared, 
Bantus were more likely to report older age at first pregnancy (72.3% vs. 58.8% ≥20 years) 
and younger age at menopause (62.2 vs. 43.9% <50 years).
Tumor pathology characteristics (among those with definitive surgery)
Overall, 31.4% of the 396 tumors with definitive surgery were ≥5cm, 59.4% were 2-<5cm, 
and only 9.2% were <2 cm in size at presentation. Lymphovascular invasion (LVI) was 
identified in 75.3% of cases, lymph node metastases in 58.8%, and extranodal extension of 
tumor in 39.1% (Table 3a).
In post hoc analyses, we found that the most highly educated patients had the smallest 
tumors (data not shown). Thus, in multivariate models evaluating the relation of ethnicity 
with tumor size, we adjusted for education level as well as age and ER status; we found that 
Nilotes tended to be more likely than Bantus to present with larger tumors (≥5cm vs. <2 
cm), (OR: 3.86, 95% CI: 0.77, 19.30; p-trend=0.10). Continuing to compare patients from 
the two major ethnic groups, we additionally found that Nilotes were more likely to present 
with LVI (OR: 1.70, 95% CI: 0.68, 4.24), and were less likely to show extra nodal extension 
(OR: 0.92, 95% CI: 0.45, 1.85), although none of these associations was statistically 
significant (Table 3b).
Hormone receptor status
Overall, 68.8% of the patients were ER positive, 59.4% were PR positive, and 25.6% were 
HER2 positive (Table 4a). Categorized by molecular subtypes, 70.2% of patients were 
Luminal A or B (ER and/or PR positive and any HER2 status), 10.6% were HER2 enriched 
(ER and PR negative and HER2 positive), and 19.2% were triple negative (ER, PR and 
HER2 negative).
In multivariate analyses evaluating the association between Bantu or Nilote ethnicity with 
molecular tumor subtype, Nilotes tended to be more likely to be present with ER negative 
tumours (36.8% versus 29.7%), although this was not statistically significant (p=0.11) and 
HER2 enriched tumors as compared with Luminal A/B cases, although this difference was 
also not statistically significant (OR: 1.41, 95% CI: 0.79, 2.49). Ethnicity was not associated 
with the likelihood of having a triple negative tumor (OR: 1.09, 95% CI: 0.67, 1.76) (Table 
4b).
DISCUSSION
This is the largest case series of histologically proven invasive breast cancers from East 
Africa that has extensive and uniform risk factor information, uniform histology review, and 
tumor hormone receptor status measured by immunohistochemistry in a single accredited 
pathology laboratory. More than eight hundred cases were enrolled over a three-year period 
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from 11 public, faith-based and private institutions that serve a full range of the geography 
and population centers in Kenya.
We observed significant differences in some socio-demographic and reproductive 
characteristics by ethnicity. For the largest two ethnic groups, the Bantus were significantly 
more likely to be more educated, more overweight or obese, older at first pregnancy, and 
younger at menopause in comparison with the Nilotes. We found no statistically significant 
differences, however, in breast tumor characteristics in women from the two major ethnic 
groups, although the Nilotes tended to present with somewhat larger tumors and to have a 
slightly higher proportion of HER2-enriched tumors when compared with the Bantus. These 
ethnic differences are likely multifactorial in nature, reflecting variations in socioeconomic, 
environmental and genetic factors.
We used tumor size, tumor grade, LVI, lymph node metastasis, and extranodal extension of 
the tumor as biologic indicators of tumor aggressiveness. Whether the non-significantly 
larger tumor sizes seen among the Nilotes reflects more aggressive tumor biology or a 
consequence of longer delay in presentation and diagnosis is an area worthy of further 
exploration. In a post hoc analysis, we observed an inverse relationship between tumor size 
and level of education. Lack of or fewer years of education may limit a woman’s awareness 
of breast cancer and her knowledge of breast cancer symptoms and the importance of 
evaluating breast lumps, may lead to delays in presentation and diagnosis.[11] Differences in 
traditional beliefs and cultural practices among ethnic groups may also explain differences in 
time to presentation and tumor size at presentation.[12] Exploring these barriers to late 
presentation among the various communities warrants further study.
Numerous studies of diverse populations have suggested that socio-demographic factors are 
likely important for ethnic differences in breast cancer tumor size and stage at diagnosis. For 
example, Awadelkarim et al reported differences in tumor characteristics between Sudanese 
and Italian women; Sudanese women tended to present with larger tumors than their Italian 
counterparts (48 mm vs. 22 mm), they had a higher proportion of aggressive grade 3 tumors 
(68% vs. 21%), and their tumors were more likely to have nodal involvement (90% vs. 
36%).[13] Additionally, a US registry-based study of the 10 largest population groups in the 
US, including Hispanic, White, Black, Japanese, Filipino, Chinese, Hawaiian, Korean, 
Vietnamese, and American Indian women diagnosed with breast cancer, reported that among 
the Japanese and White patients, tumors were smaller in size, had a lower tumor grade (even 
after adjusting for stage), and were diagnosed at an earlier stage, whereas Black and 
Hispanic patients were more likely than other groups to have tumors ≥2 cm in diameter, to 
have poorly differentiated tumors, and to be diagnosed with metastatic disease.[14] Apart 
from possible differential exposure to carcinogens and genetic susceptibility, the known 
disparities in population mammography screening levels and subsequent follow-up care may 
also be contributory factors.[14] In Kenya, screening for breast cancer is opportunistic and 
there is currently no national breast cancer-screening program in place.
Although we found suggestive differences in tumor hormone receptor and HER2 status 
between the Nilotes and Bantus, these differences were not statistically significant. Nilote 
tumors tended to be more likely to be ER negative and more likely to be HER2 positive, 
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suggesting biologically more aggressive receptor phenotypes among the Nilotes. There are 
multiple reports of variation in tumor hormone receptor and HER2 status in different ethnic 
groups. An NCI study in the SEER registry database which examined 360,933 breast cancer 
cases diagnosed between 1988-2006 showed that the Asian Indian/Pakistani women had 
more ER/PR negative breast cancer than Caucasians (30.6% vs. 21.8%, p = 0.0095).[15] 
Another study reported that relative to non-Hispanic Whites, women of African, Native 
American, South East Asian, Mexican, South/Central American, and Puerto Rican descent 
living in the United States had 1.4 to 3.1-fold elevated risks of presenting with ER and PR 
negative breast cancer.[16] This report concluded that breast cancer tumor characteristics 
differ by race/ethnicity in the United States and that both biological and lifestyle factors 
likely contribute to these findings.[16] This hypothesis that the proportions of breast cancer 
molecular subtypes differ by racial/ethnic groups is also supported by recent reports that 
East African migrants to the US tend to have less ER negative breast cancer than migrants 
from West Africa.[17]
The mean and median ages of breast cancer diagnosis (49 and 48 years, respectively) for all 
ethnicities combined in our study population were not different from those previously 
reported from Kenya.[10][18] It is noteworthy that there was a markedly earlier age at 
diagnosis among the Cushites versus the two larger ethnic groups. Although this difference 
in age at presentation may be suggestive of differences in tumor biology among the ethnic 
groups, it could also be a chance finding due to the small number of Cushites in our patient 
population.
Over 60% of the Bantus and Nilotes in this study resided in rural areas, and about half 
reported menarche at more than 15 years of age, consistent with the findings of a 
Cameroonian study which reported a higher mean age at menarche for women residing in 
rural areas (14.3 years) as compared to those residing in urban areas (13.8 years).[19] A 
significantly greater proportion of Bantus reported age at menopause < 50 years compared to 
the Nilotes and Cushites. Interestingly, a multiethnic cohort study of non-Latina Whites, 
Japanese Americans, African-Americans, Native Hawaiians, and Latinas, which investigated 
factors influencing the timing of natural menopause among 95,704 women, found that race/
ethnicity was a significant independent predictor of the timing of natural menopause. While 
African Americans did not differ significantly from non-Latina Whites, natural menopause 
occurred earlier among Latinas and later among Japanese Americans, supporting the 
hypothesis that the timing of natural menopause is driven by a combination of genetic, 
reproductive, and lifestyle factors.[20] Recently, genome-wide association studies (GWAS) 
have identified single-nucleotide polymorphism markers that are associated with ages at 
menarche[21] and menopause[22], which may aid in our understanding of the biology of 
menarche and menopause.
Differences in body mass were noted between Bantus and Nilotes, with a significantly 
higher proportion of Bantu patients being overweight or obese (BMI≥25 kg/m2). This may 
well reflect the dietary habits of the study population. As cited by Christensen et al,[23] a 
cross-sectional study in Kenya evaluating the prevalence of obesity among rural Luo 
(representing the Nilotes), who mainly subsist on maize, sorghum and fish, and rural Kamba 
(representing the Bantus), who subsist on maize, reported higher weights and BMIs in the 
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latter. In a study of rural and urban Kenyan women, the Kamba (Bantus) had the highest 
Arm Muscle Area (AMA) and the highest BMI and Arm Fat Area (AFA) as compared with 
the Luo or the Maasai (both Nilotes), a finding which was marginally significant.[23] 
Additionally, there were differences related to the location of residence in the prevalence of 
overweight (≥BMI 25 kg/m2) women among all the rural and urban female populations 
(19.5% and 60.3%, respectively).[23] In our study, there was no difference in Bantu and 
Nilote cases with respect to rural or urban location of residence, which suggests that location 
of residence may not contribute to ethnic differences in BMI observed in our patient 
population.
Interestingly, the mean age at first pregnancy was significantly younger for the Cushite 
patients than for patients from the other ethnic groups. The Somali, Rendile, Oromo and 
Borana make up the Cushitic ethnic minority, who reside in the semi-arid and arid North 
Eastern region of Kenya. Traditionally within these communities, girls usually get married 
before the age of 20 years. As prior studies have suggested, a full-term pregnancy before the 
age of 20 years may have a transient cancer promoting effect as each pregnancy, including 
the first one, may increase the risk of early-onset breast cancer [24][25][26], so early 
marriages and subsequent early pregnancies could contribute to the higher proportion of 
early onset pre-menopausal breast cancers seen in the Cushites vs. the other two ethnic 
groups, although the cross-sectional nature of the study design along with the small number 
of Cushite cases limits our ability to draw conclusions.
The great majority of patients in all three ethnic groups reported lifetime breastfeeding of 
more than 15 months, and there was no significant difference in the length of cumulative 
breast feeding by ethnic group. These results are similar to those of a previous report of 
mean cumulative breast feeding in the major ethnic tribes in Kenya: 12.1 months for the 
Kamba (Bantus), 15.6 months for the Kikuyu (Bantus), and 17.1 months for the Luo 
(Nilotes), with no significant differences among these ethnic groups.[27] Based on findings 
from a large African American cohort study, it has been hypothesized that an early first birth 
without subsequent breastfeeding is associated with elevated risk of ER negative breast 
cancer.[28] Hence, the long lifetime duration of breastfeeding in Kenyan women of varying 
ethnicities may contribute to the observed similarities in the distribution of breast cancer 
molecular subtypes by ethnicity in our study population.
Strengths of this study include the relatively large size of this African case series; the broad 
national representation of the major ethnic groups in Kenya, with the majority being of 
Bantu ancestry (67% versus 30% Nilotes)[29]; the use of uniform questionnaires and case 
report forms; and the central pathology review and immunohistochemistry. Limitations of 
the study include the fact that it was a case series, without a control population for 
comparison, and the smaller representation of the Nilotes and Cushites, compared to Bantus, 
which limited the interpretive power of our results. Additional studies with a larger 
representation from each ethnic group and suitable population-based controls are warranted 
to further our understanding of breast cancer etiology in these populations.
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CONCLUSIONS
This case series showed no significant differences in pathologic features or the molecular 
subtypes, but significant differences in socio-demographic characteristics and reproductive 
factors, of breast cancer cases in the three major ethnic groups in Kenya. These differences 
are probably multifactorial in origin. There were insufficient cases from the Cushite ethnic 
group to conclude that all three groups were clinicopathologically similar, but the available 
data suggested that this was the case. This study suggests the need for studying ethnic 
differences in breast cancer etiology and tumor characteristics throughout the genetically 
and culturally diverse populations of sub-Saharan Africa. Such studies will clearly enhance 
our overall understanding of breast cancer etiology and behavior worldwide, and may well 
help us develop new strategies for prevention and early diagnosis.
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Fig 1a. 
Ethinic migration patterns in Africa
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Fig 1b. 
Distribution of participating study sites
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